Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;1(3):e20250106.
doi: 10.70962/jhi.20250106. Epub 2025 Jul 29.

Mepolizumab treatment in a child with inherited TYK2 deficiency

Aurélia Alimi  1 ; TYK2-consortium; Stephanie Wanin  2 , Stéphanie Boisson-Dupuis  3   4   5 , Paul Bastard  3   4   5   6
Affiliations

Mepolizumab treatment in a child with inherited TYK2 deficiency

Aurélia Alimi et al. J Hum Immun. 2025 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests J.-L.C. declares being an inventor on a patent application PCT/US2021/042741, filed 22 July 2021, submitted by The Rockefeller University, which covers the diagnosis of, susceptibility to, and treatment of viral disease and viral vaccines, including COVID-19 and vaccine-associated diseases. The other authors declare no competing interests.

Figures

Figure 1
Figure 1
A: Family pedigree showing the segregation of the TYK2 mutant (M) allele. Double lines connect the two consanguineous parents. The closed black symbol indicates the proband (patient 1, P1) with TYK2 deficiency, and the open symbols indicate healthy family members. WT: wild-type. Figure 1B: Western blotting of the EBV-B cells from P1, showing TYK2 deficiency. The TYK2, STAT1, STAT3, pSTAT1, pSTAT3 and GAPDH proteins are shown. The response to IFN-α was similar to that in patients with complete TYK2 deficiency. Figure 1C: Computed tomography of P1 showing bilateral lung opacities. Figure 1D: Initial outcome before mepolizumab treatment. RSV: respiratory syncytial virus; BAL: bronchoalveolar lavage; NIV: non-invasive ventilation; IV: intravenous. AOM: acute otitis media. ARDS: acute respiratory distress syndrome. NIV: non-invasive ventilation. VZV: varicella zoster virus. Figure 1E: Outcome after mepolizumab treatment. RSV: respiratory syncytial virus; NIV: non-invasive ventilation; IV: intravenous; IV IgG: intravenous immunoglobulin; TMP-SMX: trimethoprim-sulfamethoxazole.
See this image and copyright information in PMC

References

    1. Ogishi M, et al. , Impaired IL-23-dependent induction of IFN-gamma underlies mycobacterial disease in patients with inherited TYK2 deficiency. J Exp Med, 2022. 219(10).
    1. Kreins AY, et al. , Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med, 2015. 212(10): p. 1641–62. - PMC - PubMed
    1. Minegishi Y, et al. , Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity, 2006. 25(5): p. 745–55. - PubMed
    1. Ortega HG, et al. , Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med, 2014. 371(13): p. 1198–207. - PubMed
    1. Seto Y, et al. , Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice. J Immunol, 2003. 170(2): p. 1077–83. - PubMed

LinkOut - more resources